Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials
- 1 November 2019
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 33 (13) , 2061-2071
Abstract
Background: The ANRS COV1-COHVAC cohort was a long-term safety cohort of healthy volunteers who received preventive HIV-vaccine candidates in 17 phase I/II clinical trials. Methods: Data collected from the first vaccine candidate administration and annually after inclusion in the cohort included grade 3/4 adverse events and all grade adverse events suggestive of neurological, ophthalmological and immune disorders, self-administered questionnaires on behaviors and HIV ELISA results. Age-and-sex-standardized mortality ratios (SMRs) were calculated with respect to the French population. The cohort was early terminated in 2016 due to the absence of safety signal. Results: Of 496 volunteers, 488 were included: 355 in the 7-year prospective follow-up and 133 in the retrospective data collection only. The total follow-up after the first vaccination was 4934 person-years (median: 10 years) and 270 (76%) volunteers completed their follow-up. No relevant adverse event possibly related to the vaccine was reported. Breast cancer incidence and woman mortality did not differ from those of the French general population (standardized incidence ratio = 1.47, P = 0.45 and SMR = 0.65, P = 0.28, respectively) while man mortality was significantly lower (SMR = 0.26, P = 0.0003). At the last visit, 21/29 (72%) volunteers who received the recombinant HIV gp160 protein still showed vaccine-induced seropositivity after a median follow-up of 23 years. Only a few volunteers reported risky sexual practices (men: 20/192, women: 2/162). Conclusion: Volunteers showed a sustained high commitment. No long-term safety alert was identified during the postvaccine follow-up. Participating in vaccine trials did not increase risky behaviors for HIV infection. Vaccine-induced seropositivity may persist for more than 23 years after receiving rgp160.Keywords
This publication has 29 references indexed in Scilit:
- Social and Behavioral Consequences of Participation in HIV Preventive Vaccine Trials in the ANRS COHVAC CohortJAIDS Journal of Acquired Immune Deficiency Syndromes, 2018
- When participants get involved: reconsidering patient and public involvement in clinical trials at the MRC Clinical Trials Unit at UCLTrials, 2018
- Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccinesExpert Review of Vaccines, 2017
- Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult ParticipantsClinical and Vaccine Immunology, 2014
- Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaHuman Vaccines & Immunotherapeutics, 2013
- Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse eventsHuman Vaccines & Immunotherapeutics, 2012
- Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adultsAIDS, 2006
- Consequence or coincidence?Vaccine, 2005
- The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome researchMemórias do Instituto Oswaldo Cruz, 2005
- Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trialsVaccine, 2003